HUE032486T2 - Javított eljárás béta-hidroxi-béta-metil-butirát (HMB) adagolására - Google Patents

Javított eljárás béta-hidroxi-béta-metil-butirát (HMB) adagolására Download PDF

Info

Publication number
HUE032486T2
HUE032486T2 HUE10838355A HUE10838355A HUE032486T2 HU E032486 T2 HUE032486 T2 HU E032486T2 HU E10838355 A HUE10838355 A HU E10838355A HU E10838355 A HUE10838355 A HU E10838355A HU E032486 T2 HUE032486 T2 HU E032486T2
Authority
HU
Hungary
Prior art keywords
hmb
acid
muscle
hydroxy
beta
Prior art date
Application number
HUE10838355A
Other languages
English (en)
Inventor
John Rathmacher
John Fuller
Shawn Baier
Steve Nissen
Naji Abumrad
Original Assignee
Metabolic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Tech Inc filed Critical Metabolic Tech Inc
Publication of HUE032486T2 publication Critical patent/HUE032486T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (4)

  1. láVÍTOlT ELJÂE.4S BÈ1^\4I1ÛRC>KI»BÉ1'A-MET1.L4RITIRÂT (Il MB) ADÂGOI, ÂSÂMA igéuypontnk L Kévotmeoy, ronds tartalmaz b&amp;.v-btdto\t'hotn-moiU-vaj\3v.tt tHMB-t,s szabad sav B-IMB-sav) formájában, alkalmazás céljaitól a BMB hatékonyságának a jav kására a? adagolás során, összehasonlítva egy kalemmfo-HMB-kész ítmény agy ugyanolyan dózisának az adagolásával, i/smskároxodös xsőkkentésére stressznek kitett izomban, tzomkátosodás foks......kH i' l i m\ ást., k K. ·, Ή' ' <. av χ < ns s t ο η >,* \ >m,e unsthbasa s y'N K,s~xégcet suj\ χοΐ,ηοχ \o " xB' m. I* Készfonény alkalmazás céljából az h igénypont szerint ahol a HMB-sav egy gélfom vagy egy folyadékként van formai ázva.
  2. 3, Készítmény a/ 1, igénypont vagy a 2. îgény^>ft|-;poiihi|i.: !$*«% klkklitniöy formájában all rendelkezésre. 4 Készítmény az 1--461 .Víg igénypontok bármelyike szerint, amely egf Mnblíngváhs készítmény fornn) tóban all rendelkezésre, dk Készítmény alknlnwis céljából az előzd igénypontok bármelyike szerint, ahol a HMBfoáv a következő mennyiségben v an jelen: Cls5 grammtól 30 grammig 4 Készítmén> alkalmazás céljából hz ó igénypont szerint. ahol a líMB-mv egy alkalommal X an aüugoh n egy huszonnégy órás időtartam a lan, % Készítmény az l.-tól 4-ig igénypontok bármelyike szerint, «hol a IIMB-sav a koyéílégi mennyiségben van adagolva: 0,01 grammtól 42 grammig 11MB-sav per kilogramm teslfomeg per huszonnégy éra. 8 V í tCíoo o eh, «> müiiídt' ,cnen> pttbogen ' --- na,, V jav tu »ám, protein-kímélés tangóink „protein sparing") javítására. zsírmentes «sovány) fostrrimeg javítására, izom-í miken* ponto a, í *. n tel rstt χ,ην as« asarn t. \ x \ hpsO p utn iah lavawa vagy egy személy érzelmi álUtjxnanak Újítására, ahoi az magában foglalja bcmehitlrozl-béta^metil-vajsav folMB} adagolásál szabad sav (HMB-sav) formájában. 4 P'hárás a 8. igénypont s/c.mt, ohd a HMB-sav egy gélként vagy egy tol védőkként van fonntsiázva. '14 kijárás a 8. igénypont vagy a 9, igénypont szerinti ahol a HMB-sav egy orális készítmény v-agy xz.ifolmyvxdiss készítmény for májában áll rendelkezésre, H, Hljamo a χ >fo ló - te no a vss-x K. nebske er sru ától . Ih\!B ae a kínét ke,<> mennyiségben van jelen: 0,5 grammtól 30 grammig.
  3. 12, Eljárás a 11. igénypont szerint, ahol a IlMB-sos egy a Utalom tv t ai von adagok a egy huszonnégy órás időtartam alatt. .14 Eljárás a 8,-tói 12.-ig igénypontok bármelyike szeréit, öböl ahol a HMB-'-av a következe nvrtfx.segoen nfo-goo· , 401 ja a," ótól 4 man-tmg 11Mb \a- r-! k, vgmtnm testtömeg per huszonnégy óra. lé ktX'U'xM ,um V t, on « hm fotó v bzta , Htl vatsavo ,)IVB u xts íHMIKsav) tor májában egy gél formuládéként
  4. 15, Készítmény, amely tartalmaz, héia-hidrími-bétasooiu-vagsava! tMMB-u -znbad sav iUMB-sas'í fo< o^aban 'gv fdvadék tótmttlameké'« lő, Készítmény az 14. vagy 15. Igénypont szerint, amely egy orális készítmény vagy egy msbiingvális készítmény formájában áll rendelkezésre. i
HUE10838355A 2009-12-18 2010-12-20 Javított eljárás béta-hidroxi-béta-metil-butirát (HMB) adagolására HUE032486T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28785709P 2009-12-18 2009-12-18

Publications (1)

Publication Number Publication Date
HUE032486T2 true HUE032486T2 (hu) 2018-05-02

Family

ID=44167737

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10838355A HUE032486T2 (hu) 2009-12-18 2010-12-20 Javított eljárás béta-hidroxi-béta-metil-butirát (HMB) adagolására

Country Status (11)

Country Link
US (1) US20120053240A1 (hu)
EP (1) EP2512236B1 (hu)
JP (2) JP6077857B2 (hu)
CN (1) CN102762097B (hu)
CA (1) CA2784836C (hu)
DK (1) DK2512236T3 (hu)
ES (1) ES2608483T3 (hu)
HU (1) HUE032486T2 (hu)
PL (1) PL2512236T3 (hu)
PT (1) PT2512236T (hu)
WO (1) WO2011075741A1 (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108261547A (zh) * 2011-07-15 2018-07-10 纽斯尔特科学公司 用于调节代谢途径的组合物和方法
EP3733171B1 (en) * 2012-09-10 2023-10-25 Metabolic Technologies, LLC Compositions comprising hmb and atp as well as their use
US20140272000A1 (en) * 2013-03-14 2014-09-18 Metabolic Technologies, Inc. Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same
US9713598B2 (en) 2013-03-14 2017-07-25 Abbott Laboratories Treatment of insulin resistance associated with prolonged physical inactivity
EP2993994A4 (en) * 2013-03-14 2016-11-23 Metabolic Technologies Inc LIQUIDS AND FOODS WITH BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) IN A FREE ACID FORM
WO2015137965A1 (en) * 2014-03-14 2015-09-17 Metabolic Technologies, Inc. Liquids and foodstuffs containing beta-hydroxy-beta-methylbutyrate (hmb) in free acid form
JP2016512686A (ja) * 2013-03-15 2016-05-09 アボット・ラボラトリーズAbbott Laboratories カルシウムβ−ヒドロキシ−β−メチルブチレート、カゼインホスホペプチドおよびタンパク質を含む栄養組成物
US20150057350A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Fibrosis biomarkers and methods of using same
US10188611B2 (en) * 2013-12-18 2019-01-29 Capsugel Belguim NV Stable liquid filled hard capsule comprising beta-hydroxy-beta methylbutyric acid
WO2015105981A2 (en) * 2014-01-09 2015-07-16 Abbott Laboratories Conditional essentiality of hmb
US10293337B2 (en) 2014-01-28 2019-05-21 The Methodist Hospital Single-cell pipette assembly comprising single-cell pipette handle and single-cell pipette tip
JP6309287B2 (ja) * 2014-01-29 2018-04-11 協和発酵バイオ株式会社 3−ヒドロキシ−3−メチル酪酸カルシウム含有飲料
US20160184248A1 (en) * 2014-12-15 2016-06-30 University Of Central Florida Research Foundation Inc. Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
WO2016196637A1 (en) * 2015-06-01 2016-12-08 Metabolic Technologies, Inc. Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for decreasing fat mass
JP7114458B2 (ja) * 2015-09-16 2022-08-08 メタボリック・テクノロジーズ,インコーポレーテッド 軟組織外傷からの回復を増強するためのβ-ヒドロキシ-β-メチルブチレート(HMB)の組成物および使用方法
AU2016353003B2 (en) 2015-11-10 2021-06-10 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) as an animal feed additive
EP3402476A4 (en) * 2016-01-13 2019-09-18 Metabolic Technologies, Inc. COMPOSITIONS AND METHODS FOR USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) FOR JOINT STABILITY
MX2018008903A (es) 2016-01-21 2019-02-21 Metabolic Tech Inc COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
WO2017205673A1 (en) * 2016-05-25 2017-11-30 TSI Group Ltd. Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
EP3528801B1 (en) 2016-10-21 2024-07-17 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) and probiotics
US20200276143A1 (en) * 2016-10-21 2020-09-03 Metabolic Technologies, Inc. Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) and probiotics
JP7022420B2 (ja) * 2017-06-30 2022-02-18 株式会社東洋新薬 経口組成物
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
KR20200131810A (ko) * 2018-01-05 2020-11-24 텍사스 테크 유니버시티 오피스 오브 리서치 커머셜라이제이션 간헐적 금식과 관련된 β-하이드록시-β-메틸부티레이트 (HMB)의 조성물 및 사용 방법
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10888576B2 (en) 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US20220062216A1 (en) * 2020-08-26 2022-03-03 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857552A (en) * 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US20010008641A1 (en) * 1998-11-25 2001-07-19 R. Douglas Krotzer Nutritionally active composition for bodybuilding
US6893627B2 (en) * 2001-08-31 2005-05-17 Rutgers, The State University Of New Jersey Method for treating type 2 diabetes with an extract of Artemisia
DE10215007A1 (de) * 2002-04-05 2003-10-16 Degussa Bioactives Deutschland Verwendung von Kreatinpyruvat zur Steigerung der Ausdauer bei hochintensiven körperlichen Intervallbelastungen
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
WO2005096846A1 (en) * 2004-03-11 2005-10-20 Wiley Organics, Inc. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP1973426A2 (en) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions for preventing and reducing delayed onset muscle soreness
ES2689700T3 (es) * 2008-12-09 2018-11-15 Metabolic Technologies, Inc. Intervención nutricional para mejorar la función y resistencia muscular
JP2009155336A (ja) * 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤

Also Published As

Publication number Publication date
CN102762097A (zh) 2012-10-31
PT2512236T (pt) 2016-12-29
JP6077857B2 (ja) 2017-02-08
CN102762097B (zh) 2015-06-17
CA2784836C (en) 2019-08-20
WO2011075741A1 (en) 2011-06-23
JP2013515009A (ja) 2013-05-02
EP2512236A1 (en) 2012-10-24
JP2016026181A (ja) 2016-02-12
EP2512236B1 (en) 2016-10-19
EP2512236A4 (en) 2013-06-19
ES2608483T3 (es) 2017-04-11
CA2784836A1 (en) 2011-06-23
DK2512236T3 (en) 2017-01-16
PL2512236T3 (pl) 2017-06-30
US20120053240A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
CA2784836C (en) Improved method of administering .beta.-hydroxy-.beta.-methylbutyrate (hmb)
US20200268701A1 (en) Compositions and methods for producing elevated and sustained ketosis
JP5690261B2 (ja) β−ヒドロキシ−β−メチル酪酸および少なくとも1つのアミノ酸を含む組成物および使用法
JP2008534599A (ja) 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
EP1087779A2 (en) Compositions for increasing energy in vivo
JPWO2004019928A1 (ja) 肝疾患治療剤
US20210113501A1 (en) Method of administering beta-hydroxy-beta-methylbutyrate (hmb)
KR20230124538A (ko) 운동 없이 근육량, 근력 및 근육 기능을 개선하기 위한 β-하이드록시-β-메틸부티레이트(HMB)의 조성물 및 사용 방법
MXPA00011686A (es) Composicion que comprende acido beta-hidroxi-beta-metilbutirico y al menos un aminoacido y metodos de uso